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Elevated Staphylococcus Ceftriaxone MICs are an Etest Artifact
Brandi M. Limbago1, Virginia M. Pierce2, David R. Lonsway1, and Mary Jane Ferraro2
1Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, 
Georgia
2Massachusetts General Hospital and Harvard Medical School, Boston
To the Editor
The recent publication by Pickering et al [1] described a collection of methicillin-susceptible 
Staphylococcus aureus (MSSA) that displayed elevated ceftriaxone minimum inhibitory 
concentrations (MICs) when tested by Etest (bioMerieux, Durham, North Carolina) gradient 
diffusion and would have been called “Resistant” to ceftriaxone based on previous Clinical 
and Laboratory Standards Institute (CLSI) interpretive guidance. The authors reported that 
approximately 60% of MSSA tested at their institution would have been misclassified based 
on the current CLSI guidance, which recommends testing staphylococci only against 
penicillin and oxacillin or cefoxitin in order to infer susceptibility or resistance to other β-
lactam agents. This article was available electronically ahead of print for several months. 
Although it was subsequently retracted as “an honest error in interpretation,” we believe a 
fuller explanation of the findings could improve understanding among Clinical Infectious 
Diseases readership.
We investigated the accuracy of the initial report by performing reference broth 
microdilution (BMD), disk diffusion, and Etest [both low (0.002–32 µg/mL) and high 
(0.016–256 µg/mL) range ceftriaxone Etest products] antimicrobial susceptibility testing on 
8 pulsed field gel electrophoresis (PFGE)-matched pairs of MSSA from the Pickering study 
[1] reported to have mismatched ceftriaxone susceptibility. All 16 isolates were confirmed as 
oxacillin, cefoxitin, and ceftriaxone susceptible [2, 3] with BMD and disk methods. 
Ceftriaxone MICs obtained by both Etest products were typically higher than those obtained 
with BMD but were still in the susceptible range for 100% of isolates using the high 
concentration ceftriaxone Etest, and for 93.8% of isolates using the low concentration 
ceftriaxone Etest (1 isolate tested as intermediate). In addition, 30 consecutive, unique 
MSSA isolated from blood cultures during 2 months at a single hospital were tested against 
ceftriaxone byBMD, disk diffusion, and Etest using a single 0.5 McFarland inoculum. All 
isolates tested ceftriaxone susceptible by disk diffusion and BMD; 13 (43%) isolates tested 
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nonsusceptible with Etest (Table 1). We also note that the Etest ceftriaxone package inserts 
do not list staphylococci as an organism group for which testing has been cleared [4, 5].
In summary, it appears that the ceftriaxone resistance reported in error by Pickering et al is 
an artifact of inappropriate testing rather than an error in interpretation, which was apparent 
when reference methods were used to confirm the original findings. This report created 
considerable angst among the infectious disease community and will require ongoing 
education to dispel its conclusions. This should serve as a reminder that reports of novel 
antimicrobial resistance should be confirmed by a reference method prior to publication, and 
that antimicrobial susceptibility testing should only be performed with validated methods.
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Table 1
Ceftriaxone MIC of 30 Methicillin-susceptible S. aureus Tested by Broth Microdilution (BMD) or Etest
Ceftriaxone MIC Obtained
BMD Etest
N (%) susceptible 30 (100) 17 (53)
Mode MIC (µg/mL) 4 8
Median MIC (µg/mL) 4 8
MIC50 (µg/mL) 4 8
MIC90 (µg/mL) 4 16
Abbreviations: BMD, broth microdilution; MIC, minimum inhibitory concentration; S. aureus, Staphylococcus aureus.
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